Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson and increased the price target to $190.00 from $178.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terence Flynn has given his Hold rating due to a combination of factors surrounding Johnson & Johnson’s recent performance and strategic decisions. The company reported a modest beat in their third-quarter results and slightly adjusted their revenue estimates for 2025 upwards. However, the earnings per share guidance remained unchanged, indicating a cautious outlook on profitability despite the revenue increase.
Additionally, Johnson & Johnson’s decision to separate its Orthopedics business aims to enhance strategic focus and potentially boost growth in the coming years. While the company shows confidence in its long-term growth prospects, with expectations for revenue and earnings per share growth exceeding consensus estimates, uncertainties remain. These include potential impacts from tariffs, the legislative landscape, and the need for further clarity on policy dynamics. As a result, Flynn maintains a Hold rating, reflecting a balanced view of potential opportunities and risks.
In another report released today, Barclays also maintained a Hold rating on the stock with a $176.00 price target.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year.